Review




Structured Review

Pfizer Inc pfizer biontech bnt162b2 comirnaty
Pfizer Biontech Bnt162b2 Comirnaty, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/biontech+comirnaty+pfizer/med_rxiv__64898__2026__03__13__26348310-9-18-27
Average 86 stars, based on 1 article reviews
pfizer biontech bnt162b2 comirnaty - by Bioz Stars, 2026-09
86/100 stars

Images

Related Articles

Vaccines:

Article Title: Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Article Snippet: .. All vaccines based on the sequence of the SARS-CoV-2 ancestral spike, including the Janssen Ad26.COV2.S and the Pfizer Comirnaty BNT162b2 vaccines, elicited dramatically lower titers of neutralizing antibodies against the Omicron subvariants [ , – ]. ..

Article Title: Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
Article Snippet: .. Two COVID-19 vaccines, namely Comirnaty BNT162b2 (Pfizer Laboratories (Pty) Ltd) and Ad26.COV2.S (Janssen Johnson & Johnson), were introduced in SA. ..

Article Title: From chaos to clarity: The scientometric breakthrough in COVID-19 research.
Article Snippet: Background: The COVID-19 pandemic paralyzed the world for over three years, generating unprecedented social changes in recent human history.. Aims:We aimed to scientometrically summarize a global and temporal overview of publications on COVID-19 in the two worst years of the pandemic and its progression in early 2022, after the start of vaccination.. Methods: Using the Web of Science database, this review covered the period from late 2019 to March 2022 and included all publications identified using the following terms: “SARS-CoV-2”, “COVID-19”, “Coronavirus Disease 19”, and “2019-nCoV”.

Article Title: The Ambivalence of Post COVID-19 Vaccination Responses in Humans
Article Snippet: .. Comirnaty BNT162b2 (Pfizer, New York, NY, USA and BioNTech, Mainz, Germany) and mRNA-1273 (Moderna, Cambridge, MA, USA) are commonly used mRNA vaccines worldwide. ..

Sequencing:

Article Title: Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Article Snippet: .. All vaccines based on the sequence of the SARS-CoV-2 ancestral spike, including the Janssen Ad26.COV2.S and the Pfizer Comirnaty BNT162b2 vaccines, elicited dramatically lower titers of neutralizing antibodies against the Omicron subvariants [ , – ]. ..

other:

Article Title: Impact of Vaccination Status on Outcome of Patients With COVID‐19 and Acute Ischemic Stroke Undergoing Mechanical Thrombectomy
Article Snippet: Documentation of vaccination status of all patients included unvaccinated and vaccinated patients with at least 1 vaccine: Comirnaty (BNT162b2, Pfizer- BioNTech), Spikevax (mRNA- 1273, Moderna), Vaxzevria (ChAdOx1 nCoV- 19, AstraZeneca), and Jcovden (Ad26.COV- 2.S, Johnson & Johnson/ Janssen).

Article Title: Relapse and New-Onset of Autoimmune or Inflammatory Diseases Following Vaccination With SPIKEVAX: Pharmacovigilance Overview From the French Spontaneous Reported System.
Article Snippet: Background: COVID19 vaccination raises questions in patients with autoimmune or inflammatory diseases (AIID), not included in clinical trials.. Concern exists about the risk of activating the immune system or worsening the AIID.. However, cases of AIID flareups or newonset reported in literature are limited and do not allow conclusions to be drawn on the potential effect

Article Title: Impact of Vaccination Status on Outcome of Patients With COVID‐19 and Acute Ischemic Stroke Undergoing Mechanical Thrombectomy
Article Snippet: Among the many challenges posed by the virus is the increased risk of complications, including acute ischemic stroke (AIS), with an incidence of 6% to 46% among hospitalized patients with COVID- 19.1,2 In addition, recent studies of large series of patients with COVID- 19 infection have reported a devastating clinical outcome of patients with AIS attributable to large- vessel occlusion treated with mechanical thrombectomy (MT), with mortality rates up to 31%.3,4 Since the end of 2020, several vaccines, such as Comirnaty (BNT162b2, Pfizer- BioNTech), Spikevax (mRNA- 1273, Moderna), Vaxzevria (ChAdOx1 nCoV- 19, AstraZeneca), and Jcovden (Ad26.COV- 2.S, Johnson & Johnson/Janssen), have been approved for emergency use in response to the COVID- 19 pandemic, with growing evidence of the safety and efficacy of vaccination against the SARS- CoV- 2.5 Clinical trials have shown that the vaccines are effective in reducing the severity of COVID- 19 (duration and severity of symptoms), as well as the incidence of hospitalization, intensive care unit admission, and mortality rates.6–10 However, precise analyses of the preventive role of vaccination in patients with COVID- 19 experiencing AIS because of large- vessel occlusion are still lacking.

Article Title: Impact of Vaccination Status on Outcome of Patients With COVID‐19 and Acute Ischemic Stroke Undergoing Mechanical Thrombectomy
Article Snippet: Most patients in the VAX group had been vaccinated with Comirnaty (BNT162b2, Pfizer- BioNTech; 30/38, 62.5%), followed by Jcovden (Ad26.COV- 2.S, Johnson & Johnson/Janssen; 4/48, 8.3%) and ChAdOx1- S (AstraZeneca; 2/48, 4.2%).



Similar Products

86
Pfizer Inc pfizer biontech bnt162b2 comirnaty
Pfizer Biontech Bnt162b2 Comirnaty, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/biontech+comirnaty+pfizer/med_rxiv__64898__2026__03__13__26348310-9-18-27
Average 86 stars, based on 1 article reviews
pfizer biontech bnt162b2 comirnaty - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Pfizer Inc bnt162b2 comirnaty
Bnt162b2 Comirnaty, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/bnt162b2+%EA%B2%B0%EA%B3%BC%EB%A5%BC+%EB%95%8C+%EB%B3%BC+%EC%A2%85+%ED%95%A9%ED%95%B4+%ED%98%88%EC%95%A1%EA%B2%80%EC%82%AC/pm41791459-47-9-14
Average 86 stars, based on 1 article reviews
bnt162b2 comirnaty - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

90
BioNTech comirnaty bnt162b2
Comirnaty Bnt162b2, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/bnt162b2/pmc10091277__mmc9-99-0-5
Average 90 stars, based on 1 article reviews
comirnaty bnt162b2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioNTech bnt162b2/comirnaty
Bnt162b2/Comirnaty, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/bnt162b2/pm40624061-26-4-7
Average 90 stars, based on 1 article reviews
bnt162b2/comirnaty - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioNTech bnt162b2 comirnaty
Bnt162b2 Comirnaty, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/bnt162b2/pm40559558-41-17-19
Average 90 stars, based on 1 article reviews
bnt162b2 comirnaty - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioNTech bnt162b2 (comirnaty)
Study design of preclinical toxicity studies performed in Wistar Han Rats and domestic piglets Schematic overview of the dosing regimen and days of sacrifice for the repeated-dose study in Wistar Han rats (A) and dose-escalation study in domestic piglets (B). In a separate study, 1 male and 1 female piglet (5 weeks) received a single dose i.m. of 100 μg MOMP-encoding <t>mRNA</t> packaged in Galsomes. Blood was collected in heparin tubes 7 days after injection, and PBMCs were isolated and restimulated with MOMP peptide to assess MOMP-specific T cell proliferation. Created with Biorender.com .
Bnt162b2 (Comirnaty), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/bnt162b2/pmc12167025-28-61-60
Average 90 stars, based on 1 article reviews
bnt162b2 (comirnaty) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Pfizer Inc bnt162b2 (comirnaty)
Study design of preclinical toxicity studies performed in Wistar Han Rats and domestic piglets Schematic overview of the dosing regimen and days of sacrifice for the repeated-dose study in Wistar Han rats (A) and dose-escalation study in domestic piglets (B). In a separate study, 1 male and 1 female piglet (5 weeks) received a single dose i.m. of 100 μg MOMP-encoding <t>mRNA</t> packaged in Galsomes. Blood was collected in heparin tubes 7 days after injection, and PBMCs were isolated and restimulated with MOMP peptide to assess MOMP-specific T cell proliferation. Created with Biorender.com .
Bnt162b2 (Comirnaty), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/comirnaty+bnt162b2/bnt162b2/pmc12160596-117-14-23
Average 90 stars, based on 1 article reviews
bnt162b2 (comirnaty) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Study design of preclinical toxicity studies performed in Wistar Han Rats and domestic piglets Schematic overview of the dosing regimen and days of sacrifice for the repeated-dose study in Wistar Han rats (A) and dose-escalation study in domestic piglets (B). In a separate study, 1 male and 1 female piglet (5 weeks) received a single dose i.m. of 100 μg MOMP-encoding mRNA packaged in Galsomes. Blood was collected in heparin tubes 7 days after injection, and PBMCs were isolated and restimulated with MOMP peptide to assess MOMP-specific T cell proliferation. Created with Biorender.com .

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs

doi: 10.1016/j.omtm.2025.101493

Figure Lengend Snippet: Study design of preclinical toxicity studies performed in Wistar Han Rats and domestic piglets Schematic overview of the dosing regimen and days of sacrifice for the repeated-dose study in Wistar Han rats (A) and dose-escalation study in domestic piglets (B). In a separate study, 1 male and 1 female piglet (5 weeks) received a single dose i.m. of 100 μg MOMP-encoding mRNA packaged in Galsomes. Blood was collected in heparin tubes 7 days after injection, and PBMCs were isolated and restimulated with MOMP peptide to assess MOMP-specific T cell proliferation. Created with Biorender.com .

Article Snippet: Importantly, both animals have an immune system with high similarity to the human immune system including iNKT cells reactive to α-GC stimulation., Additionally, the frequency of iNKT cells detected in various pig tissues is comparable to the typical frequencies found in humans., A repeated-dose study was conducted in female and male Wistar Han rats, following a similar study design for BioNTech/Pfizer’s COVID mRNA vaccine, BNT162b2 (Comirnaty), as reported by Rohde et al. ( A).

Techniques: Injection, Isolation

Clinical evaluation of Wistar Han rats vaccinated with three repeated doses of 30 μg Galsome-NEO (A) Ten male and 10 female 10-week-old Wistar Han rats were randomly allocated to the clinical cohort and received intramuscularly (i.m.) in the biceps femoris three repeated doses of either 30 μg patient neo-epitope mRNA encapsulated in Galsomes (Galsome-NEO rats) or an equal volume of 9% sucrose Tris 20 mM buffer (CTRL rats). The total dose was divided over both hind legs. (B–D) Clinical parameters in male and female rats 24 h after i.m. injection with buffer (CTRL) or 30 μg Galsome-NEO. (B) Local reactions (erythema and edema) were evaluated using the Draize scoring system and received a grade 0–4 depending on the severity of the local reactions. Both injection sites were evaluated, and the highest score obtained for each rat is shown in the graph. (C) Rectal temperature 24 h post injection. (D) Body weight change (%) 24 h after injection relative to the weight of the same animal 0 h after injection. (C and D) Symbols represent individual data points and mean is indicated by a bar, statistical analyses on datasets were performed by using two-way ANOVA (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). (E) Local reactions (erythema and edema) in male and female rats 4, 24, 48, 72, and 120 h after i.m. injection with Galsome-NEO. (F) Absolute daily body weights (g) of male and female rats treated with 9% sucrose Tris 20 mM buffer (CTRL) or Galsome-NEO (mean ± SD). Images created with Biorender.com .

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs

doi: 10.1016/j.omtm.2025.101493

Figure Lengend Snippet: Clinical evaluation of Wistar Han rats vaccinated with three repeated doses of 30 μg Galsome-NEO (A) Ten male and 10 female 10-week-old Wistar Han rats were randomly allocated to the clinical cohort and received intramuscularly (i.m.) in the biceps femoris three repeated doses of either 30 μg patient neo-epitope mRNA encapsulated in Galsomes (Galsome-NEO rats) or an equal volume of 9% sucrose Tris 20 mM buffer (CTRL rats). The total dose was divided over both hind legs. (B–D) Clinical parameters in male and female rats 24 h after i.m. injection with buffer (CTRL) or 30 μg Galsome-NEO. (B) Local reactions (erythema and edema) were evaluated using the Draize scoring system and received a grade 0–4 depending on the severity of the local reactions. Both injection sites were evaluated, and the highest score obtained for each rat is shown in the graph. (C) Rectal temperature 24 h post injection. (D) Body weight change (%) 24 h after injection relative to the weight of the same animal 0 h after injection. (C and D) Symbols represent individual data points and mean is indicated by a bar, statistical analyses on datasets were performed by using two-way ANOVA (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). (E) Local reactions (erythema and edema) in male and female rats 4, 24, 48, 72, and 120 h after i.m. injection with Galsome-NEO. (F) Absolute daily body weights (g) of male and female rats treated with 9% sucrose Tris 20 mM buffer (CTRL) or Galsome-NEO (mean ± SD). Images created with Biorender.com .

Article Snippet: Importantly, both animals have an immune system with high similarity to the human immune system including iNKT cells reactive to α-GC stimulation., Additionally, the frequency of iNKT cells detected in various pig tissues is comparable to the typical frequencies found in humans., A repeated-dose study was conducted in female and male Wistar Han rats, following a similar study design for BioNTech/Pfizer’s COVID mRNA vaccine, BNT162b2 (Comirnaty), as reported by Rohde et al. ( A).

Techniques: Injection

Clinical evaluation of domestic piglets vaccinated with three increasing doses of Galsome-MOMP (A) Six male and 6 female 7-week-old piglets received intramuscularly (i.m.) in the left dorsal longitudinal muscle increasing doses of 3, 15, or 100 μg C. trachomatis major outer membrane protein (MOMP) encoding mRNA encapsulated in Galsomes (Galsome-MOMP piglets) or an equal volume of 9% sucrose Tris 20 mM buffer (CTRL piglets). (B–D) Clinical parameters in male and female piglets 24 h after i.m. injection with buffer (CTRL) or increasing doses of Galsome-MOMP. (B) Local reactions (erythema and edema) were evaluated using the Draize scoring system and received a grade 0–4 depending on the severity of the local reactions. (C) Body temperature is measured by scanning a subcutaneously implanted thermal microchip. (D) Body weight change (%) 24 h after injection relative to the weight of the same animal 0 h after injection. (C and D) Individual data are shown and bars indicate mean value, statistical analyses on datasets were performed by using two-way ANOVA but did not detect any significance. (E) Local reactions at the injection site in piglets 4, 24, 48, 72, and 96 h after i.m. injection with Galsome-MOMP. (F) Absolute daily body weights (kg) of individual male and female piglets (individual data points) treated with 9% sucrose Tris 20 mM buffer (CTRL) or Galsome-MOMP, full line represents mean weights. Images created with Biorender.com .

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs

doi: 10.1016/j.omtm.2025.101493

Figure Lengend Snippet: Clinical evaluation of domestic piglets vaccinated with three increasing doses of Galsome-MOMP (A) Six male and 6 female 7-week-old piglets received intramuscularly (i.m.) in the left dorsal longitudinal muscle increasing doses of 3, 15, or 100 μg C. trachomatis major outer membrane protein (MOMP) encoding mRNA encapsulated in Galsomes (Galsome-MOMP piglets) or an equal volume of 9% sucrose Tris 20 mM buffer (CTRL piglets). (B–D) Clinical parameters in male and female piglets 24 h after i.m. injection with buffer (CTRL) or increasing doses of Galsome-MOMP. (B) Local reactions (erythema and edema) were evaluated using the Draize scoring system and received a grade 0–4 depending on the severity of the local reactions. (C) Body temperature is measured by scanning a subcutaneously implanted thermal microchip. (D) Body weight change (%) 24 h after injection relative to the weight of the same animal 0 h after injection. (C and D) Individual data are shown and bars indicate mean value, statistical analyses on datasets were performed by using two-way ANOVA but did not detect any significance. (E) Local reactions at the injection site in piglets 4, 24, 48, 72, and 96 h after i.m. injection with Galsome-MOMP. (F) Absolute daily body weights (kg) of individual male and female piglets (individual data points) treated with 9% sucrose Tris 20 mM buffer (CTRL) or Galsome-MOMP, full line represents mean weights. Images created with Biorender.com .

Article Snippet: Importantly, both animals have an immune system with high similarity to the human immune system including iNKT cells reactive to α-GC stimulation., Additionally, the frequency of iNKT cells detected in various pig tissues is comparable to the typical frequencies found in humans., A repeated-dose study was conducted in female and male Wistar Han rats, following a similar study design for BioNTech/Pfizer’s COVID mRNA vaccine, BNT162b2 (Comirnaty), as reported by Rohde et al. ( A).

Techniques: Membrane, Injection, MicroChIP Assay

Cytokine response in rats and pigs (A) A separate cytokine cohort of 6 male and 6 female rats was included in the study to evaluate cytokine secretion in rats shortly (6 h) after injection. The rats received an i.m. injection of either 30 μg of patient neo-epitope mRNA encapsulated in Galsomes (Galsome-NEO) or an equal volume of 9% sucrose Tris 20 mM buffer (control). (B–E) Plasma cytokines (TNF-α, IL-10, IFN-γ, CXCL1, MCP-1, GM-CSF, IL-18, IL-12p70, IL-1β, IL-17A, IL-33, IL-1α, and IL-6) were measured using a LEGENDplex assay. Elevated cytokine levels after NEO-Galsome injection are shown for CXCL1 (B), IL-6 (C), MCP-1 (D), and IFN-γ (E). (F) In pigs, blood was collected from the main cohort (6 male and 6 female pigs) shortly (5 h) after injection. The piglets received an i.m. injection of 3, 15, or 100 μg MOMP mRNA encapsulated in Galsomes (Galsome) or an equal volume of 9% sucrose Tris 20 mM buffer (control). (G) Serum cytokines (IFN-α, IFN-γ, IL-1β, IL-10, IL-12/IL-23p40, IL-4, IL-6, IL-8, and TNF-α) were measured using a ProcartaPlex assay. Among these, only IL-6 showed a notable elevation ( p = 0.06). Individual data points and means are shown. Statistical analyses on datasets were performed using the Mann-Whitney test, and data points below the limit of detection (LoD) were set at the LoD value for analysis (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). Images created with Biorender.com .

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs

doi: 10.1016/j.omtm.2025.101493

Figure Lengend Snippet: Cytokine response in rats and pigs (A) A separate cytokine cohort of 6 male and 6 female rats was included in the study to evaluate cytokine secretion in rats shortly (6 h) after injection. The rats received an i.m. injection of either 30 μg of patient neo-epitope mRNA encapsulated in Galsomes (Galsome-NEO) or an equal volume of 9% sucrose Tris 20 mM buffer (control). (B–E) Plasma cytokines (TNF-α, IL-10, IFN-γ, CXCL1, MCP-1, GM-CSF, IL-18, IL-12p70, IL-1β, IL-17A, IL-33, IL-1α, and IL-6) were measured using a LEGENDplex assay. Elevated cytokine levels after NEO-Galsome injection are shown for CXCL1 (B), IL-6 (C), MCP-1 (D), and IFN-γ (E). (F) In pigs, blood was collected from the main cohort (6 male and 6 female pigs) shortly (5 h) after injection. The piglets received an i.m. injection of 3, 15, or 100 μg MOMP mRNA encapsulated in Galsomes (Galsome) or an equal volume of 9% sucrose Tris 20 mM buffer (control). (G) Serum cytokines (IFN-α, IFN-γ, IL-1β, IL-10, IL-12/IL-23p40, IL-4, IL-6, IL-8, and TNF-α) were measured using a ProcartaPlex assay. Among these, only IL-6 showed a notable elevation ( p = 0.06). Individual data points and means are shown. Statistical analyses on datasets were performed using the Mann-Whitney test, and data points below the limit of detection (LoD) were set at the LoD value for analysis (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001). Images created with Biorender.com .

Article Snippet: Importantly, both animals have an immune system with high similarity to the human immune system including iNKT cells reactive to α-GC stimulation., Additionally, the frequency of iNKT cells detected in various pig tissues is comparable to the typical frequencies found in humans., A repeated-dose study was conducted in female and male Wistar Han rats, following a similar study design for BioNTech/Pfizer’s COVID mRNA vaccine, BNT162b2 (Comirnaty), as reported by Rohde et al. ( A).

Techniques: Injection, Control, Clinical Proteomics, MANN-WHITNEY

Immune responses to Galsome vaccination in rats and piglets (A) Wistar Han rats in the clinical cohort were sacrificed 48 h (main group) or 3 weeks (recovery group) after the final injection of three successive injections of either 30 μg Galsome-NEO (Galsome-NEO) or buffer (control). Spleen and inguinal lymph node were isolated and processed for flow cytometry analysis of iNKT cells. (B) Gating strategy for identifying iNKT cells in rats. Viable cells positive for CD161 (NK1.1 receptor) and CD3 were classified as iNKT cells (CD161 + /CD3 + ). Fraction of iNKT cells within the viable cell population in the (C) spleen and (D) lymph node of control animals (3 doses of buffer) and Galsome-NEO (3 doses of 30 μg TMG NEO mRNA Galsomes) 48 h ( n = 6) and 3 weeks ( n = 4) after the final dose. (E) Heparinized blood was drawn from piglets (6 females/6 males) 4 and 7 days after the first and second dose of buffer (control) or MOMP-encoding mRNA packed in Galsomes (Galsome-MOMP). The first dose contained 3 μg mRNA and the second dose 15 μg mRNA. (F) Four and 7 days after the first and second injection, whole blood was stained to detect iNKT cells. The gating strategy is shown, with cells positive for CD3 and mouse CD1d PBS-57 tetramer identified as iNKT cells. An unloaded CD1d tetramer was included as a control to ensure specific binding. (G) Fraction of iNKT cells within the viable cell population in the blood of piglets 4 and 7 days after the first (3 μg) and second (15 μg) dose. Three piglets consistently showed elevated iNKT cell numbers and are indicated with triangle symbols. (H and I) PBMCs were isolated 7 days after the second dose (3 and 15 μg, respectively) or after a single dose of 100 μg in 2 piglets (6 weeks, 1 female and 1 male), and stained with CellTrace Violet. Cells were cultured for 4 days either in the presence of an MOMP-derived peptide (25 aa containing CD4 + and CD8 + epitopes) or in cell culture medium only. Proliferating cells were defined by decreased CellTrace Violet signal with the number of proliferating cells in the unstimulated condition (autoproliferation) subtracted. (J) In addition, cell culture supernatant of peptide-pulsed PBMCs was taken and analyzed for the presence of cytokines (IFN-α, IFN-γ, IL-1β, IL-10, IL-12/IL-23p40, IL-4, IL-6, IL-8, and TNF-α). Symbols represent individual data points and mean values are shown. Statistical analysis for immune cells was performed using the multiple t test with Holm-Sidak correction and Mann-Whitney for cytokines. No significant differences were found ( p = 0.05). Images created with Biorender.com .

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs

doi: 10.1016/j.omtm.2025.101493

Figure Lengend Snippet: Immune responses to Galsome vaccination in rats and piglets (A) Wistar Han rats in the clinical cohort were sacrificed 48 h (main group) or 3 weeks (recovery group) after the final injection of three successive injections of either 30 μg Galsome-NEO (Galsome-NEO) or buffer (control). Spleen and inguinal lymph node were isolated and processed for flow cytometry analysis of iNKT cells. (B) Gating strategy for identifying iNKT cells in rats. Viable cells positive for CD161 (NK1.1 receptor) and CD3 were classified as iNKT cells (CD161 + /CD3 + ). Fraction of iNKT cells within the viable cell population in the (C) spleen and (D) lymph node of control animals (3 doses of buffer) and Galsome-NEO (3 doses of 30 μg TMG NEO mRNA Galsomes) 48 h ( n = 6) and 3 weeks ( n = 4) after the final dose. (E) Heparinized blood was drawn from piglets (6 females/6 males) 4 and 7 days after the first and second dose of buffer (control) or MOMP-encoding mRNA packed in Galsomes (Galsome-MOMP). The first dose contained 3 μg mRNA and the second dose 15 μg mRNA. (F) Four and 7 days after the first and second injection, whole blood was stained to detect iNKT cells. The gating strategy is shown, with cells positive for CD3 and mouse CD1d PBS-57 tetramer identified as iNKT cells. An unloaded CD1d tetramer was included as a control to ensure specific binding. (G) Fraction of iNKT cells within the viable cell population in the blood of piglets 4 and 7 days after the first (3 μg) and second (15 μg) dose. Three piglets consistently showed elevated iNKT cell numbers and are indicated with triangle symbols. (H and I) PBMCs were isolated 7 days after the second dose (3 and 15 μg, respectively) or after a single dose of 100 μg in 2 piglets (6 weeks, 1 female and 1 male), and stained with CellTrace Violet. Cells were cultured for 4 days either in the presence of an MOMP-derived peptide (25 aa containing CD4 + and CD8 + epitopes) or in cell culture medium only. Proliferating cells were defined by decreased CellTrace Violet signal with the number of proliferating cells in the unstimulated condition (autoproliferation) subtracted. (J) In addition, cell culture supernatant of peptide-pulsed PBMCs was taken and analyzed for the presence of cytokines (IFN-α, IFN-γ, IL-1β, IL-10, IL-12/IL-23p40, IL-4, IL-6, IL-8, and TNF-α). Symbols represent individual data points and mean values are shown. Statistical analysis for immune cells was performed using the multiple t test with Holm-Sidak correction and Mann-Whitney for cytokines. No significant differences were found ( p = 0.05). Images created with Biorender.com .

Article Snippet: Importantly, both animals have an immune system with high similarity to the human immune system including iNKT cells reactive to α-GC stimulation., Additionally, the frequency of iNKT cells detected in various pig tissues is comparable to the typical frequencies found in humans., A repeated-dose study was conducted in female and male Wistar Han rats, following a similar study design for BioNTech/Pfizer’s COVID mRNA vaccine, BNT162b2 (Comirnaty), as reported by Rohde et al. ( A).

Techniques: Injection, Control, Isolation, Flow Cytometry, Staining, Binding Assay, Cell Culture, Derivative Assay, MANN-WHITNEY